vs
FOSTER L B CO（FSTR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
FOSTER L B CO的季度营收约是再鼎医药的1.3倍（$160.4M vs $127.1M），FOSTER L B CO同比增速更快（25.1% vs 17.1%），FOSTER L B CO自由现金流更多（$19.8M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 13.6%）
Foster L B Co.是一家总部位于美国的专业工业制造企业，主要生产销售工程通道产品、建筑组件及铁路基础设施用品，服务覆盖北美及部分全球地区的商业建筑、交通和工业领域客户。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
FSTR vs ZLAB — 直观对比
营收规模更大
FSTR
是对方的1.3倍
$127.1M
营收增速更快
FSTR
高出8.0%
17.1%
自由现金流更多
FSTR
多$46.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
13.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $160.4M | $127.1M |
| 净利润 | $2.4M | — |
| 毛利率 | 19.7% | 51.0% |
| 营业利润率 | 4.9% | -54.6% |
| 净利率 | 1.5% | — |
| 营收同比 | 25.1% | 17.1% |
| 净利润同比 | 1098.3% | — |
| 每股收益（稀释后） | $0.22 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSTRZLAB
| Q4 25 | $160.4M | $127.1M | ||
| Q3 25 | $138.3M | $115.4M | ||
| Q2 25 | $143.6M | $109.1M | ||
| Q1 25 | $97.8M | $105.7M | ||
| Q4 24 | $128.2M | $108.5M | ||
| Q3 24 | $137.5M | $101.8M | ||
| Q2 24 | $140.8M | $100.1M | ||
| Q1 24 | $124.3M | $87.1M |
净利润FSTRZLAB
| Q4 25 | $2.4M | — | ||
| Q3 25 | $4.4M | $-36.0M | ||
| Q2 25 | $2.9M | $-40.7M | ||
| Q1 25 | $-2.1M | $-48.4M | ||
| Q4 24 | $-242.0K | — | ||
| Q3 24 | $35.9M | $-41.7M | ||
| Q2 24 | $2.8M | $-80.3M | ||
| Q1 24 | $4.4M | $-53.5M |
毛利率FSTRZLAB
| Q4 25 | 19.7% | 51.0% | ||
| Q3 25 | 22.5% | 59.5% | ||
| Q2 25 | 21.5% | 60.6% | ||
| Q1 25 | 20.6% | 63.6% | ||
| Q4 24 | 22.3% | 61.5% | ||
| Q3 24 | 23.8% | 64.1% | ||
| Q2 24 | 21.7% | 64.9% | ||
| Q1 24 | 21.1% | 61.4% |
营业利润率FSTRZLAB
| Q4 25 | 4.9% | -54.6% | ||
| Q3 25 | 6.0% | -42.3% | ||
| Q2 25 | 5.3% | -50.3% | ||
| Q1 25 | -2.0% | -53.3% | ||
| Q4 24 | 2.4% | -62.6% | ||
| Q3 24 | 5.3% | -66.6% | ||
| Q2 24 | 3.2% | -76.0% | ||
| Q1 24 | 4.5% | -80.7% |
净利率FSTRZLAB
| Q4 25 | 1.5% | — | ||
| Q3 25 | 3.1% | -31.2% | ||
| Q2 25 | 2.0% | -37.3% | ||
| Q1 25 | -2.2% | -45.8% | ||
| Q4 24 | -0.2% | — | ||
| Q3 24 | 26.1% | -40.9% | ||
| Q2 24 | 2.0% | -80.2% | ||
| Q1 24 | 3.6% | -61.4% |
每股收益（稀释后）FSTRZLAB
| Q4 25 | $0.22 | $-0.05 | ||
| Q3 25 | $0.40 | $-0.03 | ||
| Q2 25 | $0.27 | $-0.04 | ||
| Q1 25 | $-0.20 | $-0.04 | ||
| Q4 24 | $-0.04 | $-0.09 | ||
| Q3 24 | $3.27 | $-0.04 | ||
| Q2 24 | $0.26 | $-0.08 | ||
| Q1 24 | $0.40 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3M | $689.6M |
| 总债务越低越好 | $42.6M | — |
| 股东权益账面价值 | $175.3M | $715.5M |
| 总资产 | $330.4M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.24× | — |
8季度趋势，按日历期对齐
现金及短期投资FSTRZLAB
| Q4 25 | $4.3M | $689.6M | ||
| Q3 25 | $3.4M | $717.2M | ||
| Q2 25 | $4.2M | $732.2M | ||
| Q1 25 | $2.6M | $757.3M | ||
| Q4 24 | $2.5M | $779.7M | ||
| Q3 24 | $3.1M | $616.1M | ||
| Q2 24 | $4.0M | $630.0M | ||
| Q1 24 | $3.1M | $650.8M |
总债务FSTRZLAB
| Q4 25 | $42.6M | — | ||
| Q3 25 | $58.6M | — | ||
| Q2 25 | $81.4M | — | ||
| Q1 25 | $82.3M | — | ||
| Q4 24 | $46.8M | — | ||
| Q3 24 | $68.4M | — | ||
| Q2 24 | $87.0M | — | ||
| Q1 24 | $77.9M | — |
股东权益FSTRZLAB
| Q4 25 | $175.3M | $715.5M | ||
| Q3 25 | $174.8M | $759.9M | ||
| Q2 25 | $174.4M | $791.7M | ||
| Q1 25 | $170.8M | $810.8M | ||
| Q4 24 | $178.3M | $840.9M | ||
| Q3 24 | $181.9M | $667.7M | ||
| Q2 24 | $147.1M | $704.2M | ||
| Q1 24 | $144.6M | $762.2M |
总资产FSTRZLAB
| Q4 25 | $330.4M | $1.2B | ||
| Q3 25 | $333.9M | $1.2B | ||
| Q2 25 | $349.9M | $1.2B | ||
| Q1 25 | $342.8M | $1.2B | ||
| Q4 24 | $334.6M | $1.2B | ||
| Q3 24 | $344.5M | $985.3M | ||
| Q2 24 | $333.3M | $987.4M | ||
| Q1 24 | $326.4M | $988.4M |
负债/权益比FSTRZLAB
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.33× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $19.8M | $-26.7M |
| 自由现金流率自由现金流/营收 | 12.3% | -21.0% |
| 资本支出强度资本支出/营收 | 1.5% | 0.5% |
| 现金转化率经营现金流/净利润 | 9.18× | — |
| 过去12个月自由现金流最近4个季度 | $25.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流FSTRZLAB
| Q4 25 | $22.2M | $-26.0M | ||
| Q3 25 | $29.2M | $-32.0M | ||
| Q2 25 | $10.4M | $-31.0M | ||
| Q1 25 | $-26.1M | $-61.7M | ||
| Q4 24 | $24.3M | $-55.8M | ||
| Q3 24 | $24.7M | $-26.8M | ||
| Q2 24 | $-5.0M | $-42.2M | ||
| Q1 24 | $-21.4M | $-90.1M |
自由现金流FSTRZLAB
| Q4 25 | $19.8M | $-26.7M | ||
| Q3 25 | $26.4M | $-35.0M | ||
| Q2 25 | $7.7M | $-33.9M | ||
| Q1 25 | $-28.7M | $-63.2M | ||
| Q4 24 | $22.3M | $-58.4M | ||
| Q3 24 | $21.7M | $-28.2M | ||
| Q2 24 | $-7.0M | $-42.9M | ||
| Q1 24 | $-24.2M | $-91.1M |
自由现金流率FSTRZLAB
| Q4 25 | 12.3% | -21.0% | ||
| Q3 25 | 19.1% | -30.4% | ||
| Q2 25 | 5.4% | -31.1% | ||
| Q1 25 | -29.4% | -59.9% | ||
| Q4 24 | 17.4% | -53.8% | ||
| Q3 24 | 15.8% | -27.7% | ||
| Q2 24 | -5.0% | -42.9% | ||
| Q1 24 | -19.4% | -104.5% |
资本支出强度FSTRZLAB
| Q4 25 | 1.5% | 0.5% | ||
| Q3 25 | 2.0% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 2.6% | 1.5% | ||
| Q4 24 | 1.5% | 2.4% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 1.5% | 0.7% | ||
| Q1 24 | 2.2% | 1.1% |
现金转化率FSTRZLAB
| Q4 25 | 9.18× | — | ||
| Q3 25 | 6.70× | — | ||
| Q2 25 | 3.61× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | -1.74× | — | ||
| Q1 24 | -4.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSTR
| Rail Technologies And Services Segment | $98.0M | 61% |
| Over Time Output Method | $26.3M | 16% |
| Services | $19.4M | 12% |
| Rail Technologies Products | $10.0M | 6% |
| Over Time Input Method | $8.3M | 5% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
